Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(14%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
14%
Ph phase_3
2
29%
Ph phase_2
3
43%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Not yet recruiting2
Completed2
Withdrawn1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 32 (33.3%)

Trials by Status

withdrawn114%
not_yet_recruiting229%
recruiting114%
completed229%
unknown114%

Recent Activity

1 active trials
Showing 5 of 7
withdrawnphase_2

IL-1 Inhibition in Early TNBC

NCT06710197
not_yet_recruitingphase_3

ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS

NCT07371689
recruitingphase_2

Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants

NCT07254000
not_yet_recruitingphase_1

Pre-emptive Anakinra for Cytokine Event Reduction

NCT06703216
completed

Kineret CAPS Post Authorisation Study

NCT02326376
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06710197Phase 2

IL-1 Inhibition in Early TNBC

Withdrawn
NCT07371689Phase 3

ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS

Not Yet Recruiting
NCT07254000Phase 2

Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants

Recruiting
NCT06703216Phase 1

Pre-emptive Anakinra for Cytokine Event Reduction

Not Yet Recruiting
NCT02326376

Kineret CAPS Post Authorisation Study

Completed
NCT00928876Phase 2

Interleukin-1 Receptor Antagonist and Insulin Sensitivity

Unknown
NCT00117091Phase 3

Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7